|1.||Weizman, Abraham: 9 articles (04/2013 - 02/2003)|
|2.||Fuchs, Camil: 5 articles (11/2013 - 02/2003)|
|3.||Poyurovsky, Michael: 5 articles (11/2013 - 02/2003)|
|4.||Kasper, S: 5 articles (04/2002 - 05/2000)|
|5.||Pashinian, Artashez: 4 articles (11/2013 - 06/2007)|
|6.||Akkaya, Cengiz: 4 articles (03/2007 - 01/2005)|
|7.||Cook, Ian A: 3 articles (10/2015 - 09/2004)|
|8.||Leuchter, Andrew F: 3 articles (10/2015 - 09/2004)|
|9.||Kotler, Moshe: 3 articles (11/2013 - 04/2006)|
|10.||Weizman, Ronit: 3 articles (04/2013 - 02/2003)|
|1.||Major Depressive Disorder (Major Depressive Disorders)
02/01/2000 - "This study demonstrated that reboxetine is significantly more effective than placebo in the treatment of hospitalized patients with severe major depressive disorder and is well tolerated."
08/01/1996 - "Reboxetine is a novel antidepressant that has been shown to be effective in the treatment of major depressive disorders. "
01/01/2007 - "In this prospective 12-week open-label study, we evaluated the effectiveness of the addition of reboxetine to 141 outpatients diagnosed with major depressive disorder, according to DSM-IV-TR criteria, who were partial responders or non-responders over a period of 6 weeks, to previous treatment in monotherapy with SSRI. "
09/01/2004 - "Twenty-five adult subjects meeting DSM-IV criteria for major depressive disorder with Hamilton Rating Scale for Depression (HAM-D) scores of >/= 17 completed a treatment trial using the experimental antidepressant reboxetine. "
04/01/2003 - "An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder."
|2.||Panic Disorder (Panic Attack)
01/01/2002 - "At last assessment, there was a significant reduction in the mean number of panic attacks (range, 9.3-1.2) and phobic symptoms (range, 8.1-3.2) in the reboxetine group compared with the placebo group (ranges, 8.5-5.8 and 7.7-5.2, respectively; p < .05). "
10/01/2002 - "Reboxetine appears to be effective in the treatment of SSRI-refractory panic disorder patients and warrants further clinical investigation."
10/01/2002 - "This study aimed to investigate the efficacy of reboxetine in the treatment of patients with panic disorder who did not respond to SSRIs. "
10/01/2002 - "The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study."
09/01/2003 - "Although SSRIs are viewed as a first-line treatment for panic disorder, these results suggest that a NA agent such as reboxetine may also have a role. "
|3.||Schizophrenia (Dementia Praecox)
09/01/2004 - "Our results suggest that the adjunctive use of reboxetine may be an effective treatment for depressive and negative symptoms in schizophrenia."
10/01/2015 - "Previous studies regarding the useful effects of reboxetine on deficit symptoms of schizophrenia have resulted in inconsistent results. "
10/01/2015 - "A total of 50 male inpatients meeting diagnosis of schizophrenia entered into a 12-week parallel group, double-blind study for random assignment to reboxetine (n = 25 patients) or placebo (n = 25 patients). "
10/01/2014 - "The results obtained evidenced that reboxetine at a dosage of 4 mg/d mildly reduced only depressive symptoms (Calgary Depression Scale for Schizophrenia: P = 0.035, Cohen d = 0.7), whereas worsening of performances on phonemic fluency (P = 0.012, Cohen d = 0.5) was observed. "
09/01/2004 - "Adjunctive use of reboxetine in schizophrenia."
|4.||Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
11/01/2010 - "The main aim of this study is to evaluate the efficacy of reboxetine, a specific noradrenergic reuptake inhibitor, in adults with attention-deficit/hyperactivity disorder (ADHD). "
01/01/2001 - "Reboxetine as a potentially effective treatment for attention deficit hyperactivity disorder."
11/01/2010 - "Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial."
01/01/2011 - "This study was designed to examine the effects of reboxetine on RT in adults with Attention Deficit-Hyperactivity Disorder (ADHD). "
04/01/2008 - "An open-label trial of reboxetine in children and adolescents with attention-deficit/hyperactivity disorder."
|5.||Sleep Initiation and Maintenance Disorders (Insomnia)
08/01/2002 - "Compared with placebo, the proportion of patients with improvement on the HAM-D agitation item and the HAM-D anxiety and insomnia factors from baseline was significantly greater with reboxetine at most assessment intervals. "
01/01/2000 - "In accordance with this observation, individual HAM-D item scores early showed significant improvements among patients treated with reboxetine when compared with those who received placebo: mood improved by day 10 (P=0.004), insomnia and interest in work and daily activities by day 14 (P=0.006 and 0.003, respectively) and somatic symptoms and anxiety by day 21 (P<0.001 in both cases). "
08/01/2002 - "Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials."
08/01/2002 - "Although reboxetine was associated with a significant (p < 0.05) increase in treatment-emergent insomnia reported as an adverse effect during the first week of treatment, very few reports of insomnia were made at subsequent evaluations. "
08/01/2002 - "In addition, the incidence of treatment-emergent agitation, anxiety, and insomnia side effects with reboxetine were examined. "
|3.||Serotonin (5 Hydroxytryptamine)
|4.||Antidepressive Agents (Antidepressants)
|1.||Drug Therapy (Chemotherapy)
|2.||Phototherapy (Light Therapy)